FDA approves combo of Opdivo plus Yervoy for advanced liver cancer

by

The U.S. Food and Drug Administration has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for adults with unresectable or metastatic hepatocellular carcinoma (HCC). The approval of Opdivo plus Yervoy was granted to Bristol Myers Squibb.

Leave A Comment

Your email address will not be published. Required fields are marked *